NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/12/2024
Voltar para busca
Dado oficial do USPTO
MOLECURE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
40
Atualização mais recente
10/12/2024
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
42
Data de depósito
20/12/2021
Data de registro
10/12/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
10/12/2024
Última transação
10/12/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
2018-00-00
Primeiro uso no comércio
2021-00-00
Código do desenho
5
Tipo de titular
03
Localização do titular
WARSZAWA POLAND, PL
Examinador
ZARICK, DIANA
Unidade examinadora
N80
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the word "MOLECURE" in stylized font.
Titulares e representantes
Titulares
M. A. (pessoa física)
OncoArendi Therapeutics S.A.
Representantes
David Orms POLSON INTELLECTUAL PROPERTY LAW PC
Classificação técnica
Classes Nice
Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Medical and pharmacological research services; research and development services in the field of antibodies; research and development services in the field of immunology; research and development in the pharmaceutical and biotechnology fields; drug discovery services; development of pharmaceutical preparations and medicines; research on the subject of pharmaceuticals; conducting clinical trials for others for pharmaceutical products; biological researchclinical research in the field of inflammatory diseases and diseases leading to tissue fibrosisimmunology and cancermedical research; medical laboratory services; scientific laboratory services; analysis of human tissues for medical research; laboratory serviceslaboratory research servicesmedical laboratory servicesscientific laboratory services relating to the production of monoclonal antibodies; medical research and scientific analysis in the field of immunology and antibodies; scientific research for medical purposes in the area of cancerous diseases; biomedical research services; biological research; research relating to biotechnology; clinical research and medical research in the field of inflammatory diseases and diseases leading to tissue fibrosisimmunology and cancer; chemical research and analysis services including analytical services relating to medicinespharmaceutical preparations and biochemistry; research laboratorieslaboratory research in the field of chemistry; scientific and biotechnology research in the field of gene therapy; DNA screening for scientific research purposes; biological researchcell separation research services; research and development services in the field of immunohistology; scientific research in the field of genetics and genetic engineering; consultancy relating to research and development in the field of therapeutics; product custom design and development of medical technology; services for the development of methods of testingdevelopment and establishment of testing specifications and procedures in the field of biotechnology and pharmaceutical fields; conducting technical project studiestechnical research in the field of pharmaceutical studies; preparation of project analysis studiesconducting scientific study in the fields of medicine and biotechnology; technical consultancy relating to product development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; advisory services relating to scientific research; providing information about the results of clinical trials for others for pharmaceutical products
Publicações
Histórico de despachos e eventos da marca no USPTO.
40 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
10/12/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
14/11/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
14/11/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/11/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/11/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/11/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/10/2024
GNRT
NON-FINAL ACTION E-MAILED
10/10/2024
CNRT
SU - NON-FINAL ACTION - WRITTEN
10/10/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/09/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/09/2024
ALIE
ASSIGNED TO LIE
12/09/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/04/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
24/01/2024
GNRT
NON-FINAL ACTION E-MAILED
24/01/2024
CNRT
SU - NON-FINAL ACTION - WRITTEN
24/01/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
24/01/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
23/01/2024
IUAF
USE AMENDMENT FILED
04/01/2024
EISU
TEAS STATEMENT OF USE RECEIVED
04/01/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
18/07/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
23/05/2023
PUBO
PUBLISHED FOR OPPOSITION
23/05/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/05/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
20/04/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
20/04/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
20/04/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
20/04/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
20/04/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/03/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/03/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
27/03/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
14/10/2022
GNRT
NON-FINAL ACTION E-MAILED
14/10/2022
CNRT
NON-FINAL ACTION WRITTEN
14/10/2022
DOCK
ASSIGNED TO EXAMINER
25/09/2022
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
07/09/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
27/12/2021
NWAP
NEW APPLICATION ENTERED
23/12/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MOLECURE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.